Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
underestimating Merck's ability to grow beyond Keytruda and has already priced in much of AbbVie's near- and medium-term upside. Wolfe upgraded Merck to Outperform from Peer Perform and set a $135 price target, saying the drugmaker is approaching a new growth cycle supported by acquisitions, pipeline catalysts and a more durable outlook for its top-selling cancer drug. Recent deals like Verona and Cidara add to Merck's revenue base, while late-stage pipeline assets and label expansion opportunities support steady growth even as Keytruda approaches loss of exclusivity. Wolfe now forecasts a five-year revenue CAGR of about 4.2%, above the Street's roughly 2.4%, which it said supports the case for near-term multiple expansion. A central pillar of the call is Keytruda. Wolfe said investors are mis-modeling the drug's patent cliff, noting exclusivity now extends to late 2029 and uptake of the subcutaneous formulation, Qlex, could soften the decline. Wolfe estimates Keytruda sales
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- JPM26: US biotech's ‘Sputnik moment,' Pfizer's obesity ambitions and Bristol Myers' big year [Yahoo! Finance]Yahoo! Finance
- Healthcare Leader Fred Hassan Appointed Executive Chair of NorstellaPR Web
- 1 Momentum Stock Worth Your Attention and 2 Facing Headwinds [Yahoo! Finance]Yahoo! Finance
- Cancer Drugs Drive Nearly One-Fifth Of Pharma Sales [zero hedge]zero hedge
- 3 Dividend Stocks to Hold for the Next 10 Years [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 10/30/25 - Beat
MRK
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- MRK's page on the SEC website